ProfileGDS5678 / 1426860_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 83% 81% 82% 83% 83% 87% 84% 86% 83% 84% 83% 84% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2012284
GSM967853U87-EV human glioblastoma xenograft - Control 26.1767983
GSM967854U87-EV human glioblastoma xenograft - Control 35.8636881
GSM967855U87-EV human glioblastoma xenograft - Control 46.0961982
GSM967856U87-EV human glioblastoma xenograft - Control 56.0900883
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9067983
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4707787
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2190284
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4572986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1883
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1667284
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1412383
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2392784
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1755584